


**Amendments to the Claims**

1. (currently amended) A benzisothiazole-3(2H)-one compound of formula (I)



(I)

wherein;

$R_1$  is the group (C4-C12)haloalkyl, -CF<sub>3</sub>, (C1-C<sub>8</sub>)alkylcycloalkyl, or (C3-C<sub>8</sub>)cycloalkyl, substituted benzyl-, and (C2-C<sub>4</sub>)alkylaryl, wherein the aryl is optionally substituted and the benzyl is substituted with 1 to 3 groups independently selected from (C1-C12)alkyl, (C2-C12)alkenyl, (C1-C12)alkoxy, and (C1-C12)haloalkyl;

$R_2$  is hydrogen;

$R_3$ ,  $R_4$ ,  $R_5$ , and  $R_6$ , are each independently selected from hydrogen, (C1-C4)alkyl, (C2-C4)alkenyl, -O-(C1-C3 alkyl), COOH, C(O)(C1-C3 alkyl), C(O)O(C1-C3 alkyl), -CF<sub>3</sub>, and halo; or a pharmaceutically acceptable salt thereof.

2. (canceled)

3. (currently amended) A compound according to Claim 1 wherein  $R_1$  is ~~allyl~~, (C3-C4)alkylcycloalkyl, or -CF<sub>3</sub>.

4. (canceled)

5. (canceled)

6. (previously presented) The compound of Claim 1 wherein  $R_5$  is the group represented by chloro, bromo or CF<sub>3</sub>.

7. (currently amended) A compound selected from the group consisting of:

3-Oxo-3*H*-benzo[d]isothiazole-2-carboxylic acid allylamide;

3-Oxo-3*H*-benzo[d]isothiazole-2-carboxylic acid cyclohexylamide;

~~3-Oxo-3*H*-benzo[d]isothiazole-2-carboxylic acid 2-methyl-benzylamide;~~

~~3-Oxo-3*H*-benzo[d]isothiazole-2-carboxylic acid 3-methyl-benzylamide;~~

~~3-Oxo-3*H*-benzo[d]isothiazole-2-carboxylic acid 4-methyl-benzylamide;~~

~~3-Oxo-3*H*-benzo[d]isothiazole-2-carboxylic acid 2-ethyl-6-methyl-benzylamide;~~

~~3-Oxo-3*H*-benzo[d]isothiazole-2-carboxylic acid 2-isopropyl-6-methyl-benzylamide;~~

~~3-Oxo-3*H*-benzo[d]isothiazole-2-carboxylic acid phenethylamide;~~

3-Oxo-3*H*-benzo[d]isothiazole-2-carboxylic acid (4-cyclohexyl-butyl)-amide; and

6-Chloro-3-oxo-3*H*-benzo[d]isothiazole-2-carboxylic acid cyclohexylamide; ~~and~~<sub>x</sub>

8. (canceled)


9. (currently amended) A pharmaceutical formulation comprising a benzisothiazole-

3(2*H*)-one compound of formula I according to claim 1, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent.

10-11. (canceled)

12. (currently amended) A pharmaceutical formulation containing a therapeutically effective amount of the compound of formula 1, or a pharmaceutically acceptable salt thereof,

wherein  $R_1$ ,  $R_2$ ,  $R_3$  are defined as in claim 1



I

wherein:

R<sub>1</sub> is the group (C<sub>4</sub>-C<sub>12</sub>)haloalkyl, -CF<sub>3</sub>, (C<sub>1</sub>-C<sub>3</sub>)alkylcycloalkyl, or (C<sub>3</sub>-C<sub>8</sub>)cycloalkyl, substituted benzyl, and (C<sub>2</sub>-C<sub>3</sub>)alkylaryl, wherein the aryl is optionally substituted and the benzyl is substituted with 1 to 3 groups independently selected from (C<sub>1</sub>-C<sub>12</sub>)alkyl, (C<sub>2</sub>-C<sub>12</sub>)alkenyl, (C<sub>1</sub>-C<sub>12</sub>)alkoxy, and (C<sub>1</sub>-C<sub>12</sub>)haloalkyl;

R<sub>2</sub> is hydrogen;

R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, and R<sub>6</sub> are each independently selected from hydrogen, (C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>2</sub>-C<sub>4</sub>)alkenyl, -O-(C<sub>1</sub>-C<sub>3</sub> alkyl), COOH, C(O)(C<sub>1</sub>-C<sub>3</sub> alkyl), C(O)O(C<sub>1</sub>-C<sub>3</sub> alkyl), -CF<sub>3</sub>, and halo;  
or a pharmaceutically acceptable salt thereof;


**formulated for the treatment of the effect of elevated hepatic lipase activity  
hypercholesterolemia, hyperlipidemia, or atherosclerosis.**

13-15. (canceled)

16. (currently amended) The method of claim ~~40~~18 wherein the benzisothiazole-3(2H)-one compound is formulated with a ~~with a~~ pharmaceutically acceptable carrier or diluent.

17. (canceled)

18. (currently amended) A method of treating hypercholesterolemia, hyperlipidemia, or atherosclerosis in a mammal in need thereof comprising administering using a therapeutically effective amount of benzisothiazole-3(2H)-one compound of formula I, wherein R<sub>1</sub>-R<sub>6</sub> are as defined in claim 1



I

or a pharmaceutical acceptable salt thereof.